Publication | Closed Access

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

Hematological MalignancyMedicineHematologyImmunologyMyeloid NeoplasiaPharmacotherapyImmunotherapyOncologyRadiation OncologyRefractory Multiple MyelomaHealth Sciences